 Connection
Shaodong Dai to Amyloid beta-Peptides
This is a "connection" page, showing publications Shaodong Dai has written about Amyloid beta-Peptides.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.048 |
|
|
|
-
Bellver-Sanchis A, Valle-Garcia D, Barbaraci C, Romero-Becerra F, Singh RK, Jarne-Ferrer J, Vasilopoulou F, Irisarri A, Martínez-Fernández C, Fafián-Labora JA, Arufe MC, Wüst C, Castellanos A, Soto D, Casals N, Fadó R, Pocock JM, Navarro G, Val C, Brea J, Loza MI, Lleó A, Fortea J, Alcolea D, Perez-Bosque A, Miró L, Pérez B, Rashid S, Ali M, Saqib M, Lí Carbó M, Guerrero A, Vázquez S, Choudhary BS, Dai S, Escolano C, Franco R, Pallàs M, Griñán-Ferré C. First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease. Mol Ther. 2026 Apr 01; 34(4):2372-2407.
Score: 0.048
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|